Manufacturer And Supplier 99% Crisaborole Powder CAS Number 906673-24-3 For Eczema
Product Description
Crisaborole powder is a topical medication specifically designed for the treatment of mild to moderate atopic dermatitis, commonly known as eczema. It is classified as a phosphodiesterase-4 (PDE-4) inhibitor, which means it works by modulating the inflammatory response in the skin. By inhibiting PDE-4, crisaborole helps to reduce the production of pro-inflammatory cytokines, thereby alleviating symptoms such as redness, itching, and inflammation.
One of the key advantages of crisaborole is its non-steroidal formulation, making it an attractive option for patients who wish to avoid corticosteroids, which can have potential side effects when used long-term. Crisaborole is applied directly to the affected areas of the skin, and its formulation allows for easy absorption without leaving a greasy residue.
Clinical studies have demonstrated the effectiveness of crisaborole in improving the severity of eczema and enhancing the overall quality of life for patients. It is suitable for use in both adults and children aged two years and older, providing a flexible treatment option for managing eczema symptoms.
Crisaborole is generally well-tolerated, with few reported side effects, such as application site reactions. This makes it a valuable addition to the therapeutic options available for atopic dermatitis, particularly for those seeking a safe and effective long-term treatment strategy. Overall, crisaborole powder represents a significant advancement in dermatological care for managing eczema.
| Item name | Crisaborole |
| CAS No. | 906673-24-3 |
| Purity | 99% |
| Package | Aluminum Bag;Drums |
| Shipment | DHL, FedEx, TNT, UPS, Post |
| Payment Term | T/T, Western Union, L/C |
| Storage | Common storage 2-8ºC, long time storage -20ºC |
| Shelf life | 2 years |
Function and Application
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole is indicated for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.
